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DObjective: Survival of high-risk patients with univentricular heart disease after Norwood palliation is reduced.
We hypothesized that early goal-directed monitoring with venous oximetry and near-infrared spectroscopy would
offset their increased vulnerability and improve survival.
Methods: A prospective database of patients undergoing stage 1 palliation was used to assess differences in out-
comes across risk groups in the setting of a comprehensive, goal-directed monitoring program. High-risk criteria
included gestational age 35 weeks or less, birth weight less than 2.5 kg, and additional cardiac or extracardiac
anomalies. Outcomes included survival to defined end points and measures of postoperative support.
Results: From September 2000 to September 2008, 162 patients underwent stage 1 palliation: 28% (45/162)
high-risk and 72% (117/162) standard-risk patients. Lesions other than hypoplastic left heart syndrome were
more common among high-risk patients (38%, 17/45, vs 15%, 18/117, P ¼ .003). Operative survival was not
statistically different(87%, 39/45, high risk vs 95%, 111/117, standard risk, P ¼ .1). High-risk patients were
more likely to receive inpatient treatment until stage 2 palliation (24%, 11/45, vs 10%, 12/117, P ¼ .001) and
had lower 1-year survival (78% vs 93%, P ¼ .01) and survival to date (71% vs 92%, P ¼ .001).
Conclusions: Intensive monitoring partially offset biologic vulnerability of high-risk patients, helping attain
comparable early outcomes. Vulnerability persisted throughout the interstage period, however, and increased
mortality beyond cavopulmonary shunt was seen only among high-risk patients. Although enhanced monitoring
reduced early mortality, high resource use and attrition after stage 2 palliation suggest an ongoing need to evaluate
our current palliative strategy for this subset of patients. (J Thorac Cardiovasc Surg 2010;140:857-63)Patient-related factors, in addition to surgical technique and
perioperative management strategies, influence outcomes
after Norwood palliation for hypoplastic left heart syndrome
(HLHS) and its variants. Recent studies have found wors-
ened outcomes among patients with prematurity, low birth
weight, extracardiac anomalies, or additional cardiac defects
and have designated these patients as at high risk for stan-
dard staged palliation because of early perioperative mortal-
ity of 50% to 70%.1-5 As a result, some centers have
developed alternative approaches for patients considered
to be at high risk for Norwood palliation.6,7 We and others
have reported improved outcomes with perioperative
monitoring strategies that include venous oximetry and
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The Journal of Thoracic and CaThere have been no studies addressing the efficacy of such
an intensive monitoring strategy for subgroups of patients
with HLHS. An intensive monitoring strategy may have
greater value for the higher risk group; alternatively,
that group may be too sick to benefit from such a strategy.
We sought to address this question in this study and
hypothesized that early goal-directed monitoring with
venous oximetry and near-infrared spectroscopy would
offset the increased vulnerability of these high-risk patients
and improve their operative survival and survival to stage 2
palliation.MATERIALS AND METHODS
Patients
This is an observational study from a human research review board–ap-
proved prospective database of 162 patients who underwent stage 1 pallia-
tion (S1P) for univentricular heart disease at Children’s Hospital of
Wisconsin from September 2000 to September 2008. This cohort was man-
aged with a comprehensive monitoring program including postoperative ve-
nous oximetry and heightened interstage surveillance until bidirectional
cavopulmonary shunt. Two-site near-infrared spectroscopic monitoring of
regional perfusion was introduced in May 2002. Forty-five of the 162 pa-
tients (28%) within this cohort were considered high-risk patients and
had at least 1 of the following concomitant diagnoses: 35 weeks gestation
or less, birth weight less than 2.5 kg, additional cardiac anomalies, or extrac-
ardiac anomalies. High-risk patients were compared with 117 of 162
standard-risk patients (72%).rdiovascular Surgery c Volume 140, Number 4 857
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
HLHS ¼ hypoplastic left heart syndrome
S1P ¼ stage 1 palliation
SaO2 ¼ arterial oxygen saturation
SrO2 ¼ regional tissue oxygen saturation
SvO2 ¼ venous oxygen saturation
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All patients within this cohort underwent S1P with either a modified Bla-
lock–Taussig shunt or a right ventricle–pulmonary artery conduit. The right
ventricle–pulmonary artery conduit was introduced as the provision for pul-
monary blood flow in October 2003. Previously described surgical tech-
nique included relief of aortic arch obstruction by means of coarctectomy,
augmentation of the aortic arch with allograft pulmonary artery, and side-
to-side anastomosis of the aortic and pulmonary roots with a proximal cut
back below the sinotubular ridge of the pulmonary root.14 All patients
were supported with deep hypothermic cardiopulmonary bypass with ante-
grade cerebral perfusion through a shunt sewn on polytetrafluoroethylene
graft anastomosed to the innominate artery. Brief circulatory arrest was
used during the atrial septectomy in all cases and during arterial cannula
repositioning in patients with modified Blalock–Taussig shunts. Modified
ultrafiltration was used in all cases. Methylprednisolone (10 mg/kg) was
routinely administered at 8 hours and 2 hours before surgery. Aprotinin
(1.7 3 106 KIU/m2) was administered intravenously before skin incision,
in the bypass circuit prime, and as a continuous infusion of 4.0 3 105
KIU/(m2 $ h) during the procedure in 154 consecutive patients. The most re-
cent 8 patients who could not receive aprotinin received aminocaproic acid
(75 mg/kg loading to the patient and to the circuit prime, followed by infu-
sion at 75 mg/[kg $ h] until surgery end). Phenoxybenzamine (0.25 mg/kg)
was added to the pump prime according to a human research review board–
and Food and Drug Administration–approved protocol and investigational
new drug exemption. Oximetric catheters were surgically placed in the su-
perior vena cava before separation from cardiopulmonary bypass.15 Milri-
none was initiated during rewarming, and epinephrine and norepinephrine
were titrated during separation from bypass to achieve an approximate sys-
temic vascular resistance index of 12 Wood units, adequate inotropy, and
goal-directed end points. All patients underwent delayed sternal closure.
Postoperative Management
Standardized postoperative monitoring including continuous invasive
arterial blood pressure, central venous pressure, arterial saturation (SaO2;
Masimo Corp, Irvine, Calif), and venous saturation (SvO2; Abbott Labora-
tories, Abbott Park, Ill), with blood drawn from the superior vena cava was
used for this cohort. In the most recent 129 patients, 2-site (cerebral and so-
matic) regional oximetry with near-infrared spectroscopy (INVOS 5100A;
Somanetics Corporation, Troy, Mich) was used to assess regional tissue
oxyhemoglobin saturation (SrO2).
15 Postoperative management targets
were SaO2 greater than 75%, SvO2 greater than 50%, cerebral SrO2 greater
than 50%, somatic SrO2 greater than 60%, mean arterial pressure greater
than 45 mm Hg, diastolic blood pressure greater than 30 mm Hg, and atrial
pressure less than 12 mm Hg.
Interstage Management
After S1P, patients discharged to home participated in an interstage mon-
itoring program, with daily assessments of SaO2 and weight by parents until
cavopulmonary shunt. SaO2 less than 75% at rest, weight loss, or failure to
gain weight prompted investigation on either an outpatient or inpatient basis
to rule out an intercurrent illness or an anatomic lesion as the etiology of the858 The Journal of Thoracic and Cardiovascular Surgmonitoring abnormality.8,11 Patients thought to be at increased risk for
interstage mortality because of significant atrioventricular valve
insufficiency, arrhythmias, or extracardiac concerns remained in the
hospital until further surgical intervention.
Timing of Bidirectional Cavopulmonary Shunt
Current practice at Children’s Hospital of Wisconsin includes elective
cavopulmonary anastomosis between 4 and 5 months of age. Practice is
based on analysis of trends in arterial oxygenation and growth in a cohort
of home-monitored patients after S1P, with earlier progression to cavopul-
monary anastomosis for patients found to have excessive hypoxemia,
growth failure, or symptoms of progressive heart failure.11,16 Patients
thought to be poor candidates for further single-ventricle palliation are listed
for transplant.
Data Analysis
Early and intermediate outcomes compared between high-risk and
standard-risk groups included operative mortality (defined as occurring
within 30 days after surgery in or out of hospital or after 30 days during
the same hospitalization), ability to achieve superior cavopulmonary anas-
tomosis, 1-year survival, and survival to date. A perioperative hemody-
namic database containing parameters prospectively acquired for 48 hours
was used for hemodynamic comparison between groups. Continuously
measured parameters included SaO2 (Masimo SET on GE Solar), SvO2
(4F Oxycath; Abbott), mean arterial pressure, heart rate, central venous
pressure (transthoracic atrial line), frontal cerebral and T12-L2 somatic
SrO2 values (Somanetics 5100B/C pediatric sensors), end-tidal PCO2 (Nova-
metrix main stream CapnoStat/GE Solar; Respironics, Inc, Murrysville, Pa),
and inspired oxygen fraction. Periodic measures included arterial hemoglo-
bin concentration, arterial PCO2, arterial PO2, pH, base excess interpolated to
hourly measures, and vasoactive drug infusion rates. Derived variables in-
cluded pulmonary to systemic flow ratio ([SaO2SvO2]/(97SaO2, assum-
ing pulmonary capillary saturation of 97%), arteriovenous oxygen content
difference, systemic and pulmonary vascular resistance indices (assuming
an oxygen consumption of 160 mL/[m2 $min]), and physiologic dead space
([arterial PCO2  end-tidal PCO2])/arterial PCO2). Need for extracorporeal
membrane oxygenation (ECMO) after S1P, placement of enteral feeding
tube, interstage management, age and weight at second-stage palliation,
and transplant status were also compared between groups.
Data were expressed as mean  SD for continuous variables and as me-
dian with range or 5% to 95% confidence intervals when appropriate. Cat-
egoric variables are described as counts and percentages. High-risk versus
standard risk patients were compared for categoric outcome variables with
the c2 statistic or Fisher’s Exact test. The effect of imbalances in treatment
factors between risk groups was corrected by propensity score matching
and reported as the average effect attributable to the risk group. Kaplan–
Meier actuarial survival analysis with log-rank comparison between groups
was used to compare overall survival. The differences in mean values of
hemodynamic parameters and support levels between high-risk and
standard-risk groups were assessed by mixed-model time-series regression
techniques. The cutoff for significance was P< .05 after multiple compar-
ison correction with the Tukey honestly significant difference or the Bon-
ferroni method, as applicable. All statistical analyses were performed
with SPSS Version 17.0 (SPSS Inc, an IBM Company, Chicago, Ill) and
Stata Version 10 (StataCorp LP, College Station, Tex).RESULTS
From September 2000 through September 2008, a total of
162 patients underwent S1P. Operative survival for this co-
hort was 92%. Survival to cavopulmonary shunt or inter-
stage cardiac transplant (5 patients) was 91%, survival to 1
year of age was 90%, and survival to date was 86%. Withinery c October 2010
TABLE 1. Additional diagnoses for high-risk group
Diagnosis No.
Low birth weight (2.5 kg) 15
Prematurity (35 gestational wk) 10
Additional cardiac anomalies 7
Anomalous venous drainage 3
Anomalous origin of coronary artery 1
Left atrial thrombus 1
Intact atrial septum 1
Congenital heart block 1
Extracardiac anomalies 32
Airway or respiratory 7
Bilateral vocal cord paralysis 2
Cleft palate, micrognathia 1
Respiratory distress syndrome 3
Right lung hypoplasia (scimitar) 1
Gastrointestinal or hepatic 8
Heterotaxy without malrotation 2
Heterotaxy with malrotation post Ladd procedure 3
Gastroschisis 1
Anorectal malformation 1
Liver hemangiomas 1
Genitourinary 3
Ambiguous genitalia requiring surgery 1
Solitary kidney with hydroureter 1
Renal hemangiomas 1
Skeletal or vertebral 3
Neurologic 2
Arnold–Chiari malformation 1
Hypoplastic corpus callosum, intracranial cysts 1
Factor V Leiden 1
Congenital hypothyroidism 1
Genetic 7
Turner syndrome 4
DiGeorge syndrome 1
Chromosome 15 microdeletion 1
Dysmorphic features, unassigned metabolic disorder 1
Several patients had more than 1 high-risk diagnosis.
TABLE 2. Patient characteristics by risk level
High
(n ¼ 45)
Standard
(n ¼ 117)
P
value
Birth weight (kg, mean  SD) 2.6  0.6 3.3  0.5 <.001
Gestational age (wk, mean  SD) 37.0  1.7 38.5  1.1 <.001
Sex (no. male) 23 (51%) 75 (64%) .09
Prenatal diagnosis (no.) 22 (49%) 69 (59%) .4
HLHS* (no.) 28 (62%) 99 (85%) .003
Aortic atresia, mitral atresia 15 (33%) 51 (44%)
Aortic atresia, mitral stenosis 1 (2%) 15 (13%)
Aortic stenosis, mitral stenosis 12 (27%) 33 (28%)
Other univentricular lesions (no.) 17 (38%) 18 (15%)
Right ventricle dominant
Unbalanced atrioventricular canal 4 (9%) 4 (3%)
HLHS, ventricular septal defect,
arch obstruction
4 (9%) 0
Double-outlet right ventricle,
mitral atresia
2 (4%) 3 (3%)
Left ventricle dominant
Double-inlet left ventricle 4 (9%) 3 (3%)
Tricuspid atresia, transposition
of great arteries
3 (7%) 8 (7%)
Ascending aortic diameter
(mm, mean  SD)
4.0  1.8 3.5  1.7 .1
HLHS, Hypoplastic left heart syndrome. *Per the International Working Group for
Mapping and Coding of Nomenclatures for Paediatric and Congenital Heart Disease.17
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high risk and 72% (117/162) were considered standard
risk. High-risk diagnoses are shown in Table 1. Several pa-
tients had multiple high-risk diagnoses. Comparisons of pa-
tient characteristics and cardiac diagnostic categories
between groups are shown in Table 2. Univentricular lesions
other than HLHS, as defined by the International Working
Group for Mapping and Coding of Nomenclatures for Paedi-
atric and Congenital Heart Disease,17 were more common
among high-risk patients (38%, 17/45, vs 15%, 18/117,
P ¼ .003). Of the 5 patients with heterotaxy, 1 patient had
aortic atresia with mitral atresia, 3 patients had right ventri-
cle–dominant atrioventricular canal, and 1 patient had
double-inlet left ventricle.
Intraoperative support times (cardiopulmonary bypass in-
cluding antegrade cerebral perfusion, circulatory arrest, and
total support times) were longer in the high-risk group. NeedThe Journal of Thoracic and Cafor postoperative ECMO support within 30 days of S1P was
similar between groups: 8 of 45 patients (18%) in the high-
risk group versus 15 of 117 patients (13%) in the standard-
risk group. Six patients in each group (13% in high-risk
group and 5% in standard-risk group, P¼ .095) were placed
on ECMO support during the first 24 hours after S1P for
catecholamine-resistant shock. No patient in the high-risk
group was placed on ECMO for shunt thrombosis, versus
4 patients in the standard-risk group. One additional high-
risk patient and 3 standard-risk patients were placed on
ECMO for cardiac failure between postoperative days 3
and 15. High-risk patients had longer duration to delayed
sternal closure (7.9  8.4 days vs 4.1  5.5 days,
P ¼ .002) and longer hospital stay (48  25 days vs 34 
15 days, P< .001).
Operative survival was comparable between groups: 39 of
45 patients (87%) in the high-risk group versus 111 of 117
patients (95%) in the standard-risk group (P ¼ .1; Table 3).
Deaths within 30 days of surgery among high-risk patients
included a low–birth weight infant with dysmorphic features
and an initial attempt at 2-ventricle repair and a second infant
with intact atrial septum who underwent atrial septectomy at
1 hour after birth, followed by bilateral pulmonary artery
banding on day 5 after birth and S1P on day 15 after birth.
These infants died on postoperative days 8 and 29, respec-
tively. The 3 early deaths in the standard-risk group were
those of an infant with decreased oral intake while at
home on postoperative day 29, a second infant with shuntrdiovascular Surgery c Volume 140, Number 4 859
TABLE 3. Stage 1 palliation operative, postoperative, and interstage
variables by risk level
High
(n ¼ 45)
Standard
(n ¼ 117)
P
value
Age at S1P (d, mean  SD) 9.3  6.1 7.2  6.5 .06
Total support time (min, mean  SD) 210  95 183  47 .04
Cardiopulmonary bypass
(min, mean  SD)
200  80 175  44 .02
Circulatory arrest (min, mean  SD) 16  18 10  5 .002
Modified Blalock–Taussig shunt (no.) 24 (53%) 84 (72%) .02
Time to delayed sternal closure
(d, mean  SD)
7.9  8.4 4.1  5.5 .002
Extracorporeal membrane oxygenation
support within 30 d of S1P (no.)
7 (16%) 13 (11%) .6
Operative survival (no.) 39 (87%) 111 (95%) .1
S1P hospital stay (d, mean  SD) 48  25 34  15 <.001
Gastrostomy tube (no.) 22 (49%) 38 (32%) <.001
Interstage management (no.)
Home monitoring 26 (58%) 99 (85%) .001
Interstage event 17 (65%) 56 (57%) .5
Interstage death 0 3 (3%) <.999
Inpatient monitoring 11 (24%) 12 (10%) .001
Transplant 2 (4.4%) 3 (2.6%) .5
Achieved cavopulmonary shunt (no.) 37 (82%) 108 (92%) .08
Age at cavopulmonary
shunt (d, mean  SD)
129  42 114  34 .03
Weight at cavopulmonary
shunt (kg, mean  SD)
5.3  1.4 5.4  0.9 .7
Survival at 1 y (no.) 35 (78%) 109 (93%) .01
Survival to date (no.) 32 (71%) 108 (92%) .001
S1P, Stage 1 palliation.
TABLE 4. Unadjusted survival outcomes by shunt type within high-
risk and standard-risk groups
Operative
survival
Survival
at 1 y
Survival
to date
High risk (n¼45)
Right ventricle–pulmonary artery
shunt (n ¼ 24)
81% 76% 67%
Modified Blalock–Taussig
shunt (n ¼ 21)
92% 79% 75%
P value .4 >.999 .7
Standard risk (n ¼ 117)
Right ventricle–pulmonary artery
shunt (n ¼ 33)
100% 97% 94%
Modified Blalock–Taussig
shunt (n ¼ 84)
93% 92% 92%
P value .2 .4 .7
TABLE 5. Propensity-matched predicted outcomes between risk
groups
Outcome Control High risk ATT* P value
Operative survival 0.98  0.15 0.83  0.38 0.14  0.08 .09
Survival at 1 y 0.88  0.32 0.72  0.46 0.16  0.10 .09
Survival to date 0.88  0.32 0.66  0.48 0.22  0.10 .04
ATT, Average effect of the treatment on the treated. *The average effect of assignment
to high-risk group on outcome is expressed after correction for the propensity to re-
ceive a right ventricle–pulmonary artery shunt in each group. There was a significant
reduction in predicted outcome in the high-risk group in terms of late survival.
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moderate atrioventricular valve insufficiency during feeding
on postoperative day 30.
S1Pwith a modified Blalock–Taussig shunt was less com-
mon in the high-risk group (P ¼ .02). Shunt type received
was not associated with unadjusted outcome in either the
high-risk or the standard-risk group (Table 4). After correc-
tion for the higher frequency of right ventricle–pulmonary
artery conduits in the high-risk group by propensity scoring,
there was a reduction in the predicted intermediate survival
in the high-risk group (Table 5).
Mortality later than 30 days after S1P but during the same
hospitalization consisted of 4 high-risk patients and 3
standard-risk patients. Within the high-risk group, 1 infant
with respiratory distress syndrome with an initial attempt at
2-ventricle repair died on ECMO awaiting cardiac transplan-
tation at 11 weeks of age; 1 multiple-gestation infant with re-
spiratory distress syndrome and chronic lung disease died at
10 weeks of age; 1 low–birth weight infant with congenital
hypothyroidism died at 11 weeks of age; and 1 infant with
heterotaxy, asplenia, and total anomalous pulmonary venous
return died at 6 weeks of age.Within the standard-risk group,
1 infant with shunt thrombosis died at age 7 weeks, an infant
awaiting transplant died at age 13 weeks, and a third infant860 The Journal of Thoracic and Cardiovascular Surgdied at age 11 weeks on the morning of his scheduled early
cavopulmonary shunt for cardiac failure with electrocardio-
graphic evidence of coronary ischemia and coronary ostial
stenosis identified on postmortem examination.
Comparisons between groups of early hemodynamics and
vasoactive support after S1P are shown in Table 6. Arterial
SaO2, SvO2, arteriovenous oxygen content difference, pulmo-
nary to systemic flow ratio, central venous pressure, and
heart rate were similar between high-risk and standard-risk
groups. Parameters including mean arterial pressure, pH,
base excess, and somatic SrO2 were within targeted ranges
for both groups but statistically lower among the high-risk
patients than among the standard-risk patients.
High-risk patientsweremore likely to bemanaged as inpa-
tients during the interstage period, whereas standard-risk pa-
tients were more commonly monitored at home (P ¼ .001).
Incidence of breach of home monitoring criteria (a fall in
SaO2 or inadequate weight gain) was similar between groups
(Table 3).
Thirty-seven of 45 high-risk patients (82%) and 108 of
117 standard-risk patients (92%) went on to subsequent
palliation with a cavopulmonary shunt (P ¼ .08). Weight at
cavopulmonary anastomosis was similar between groups;
however, high-risk patients underwent cavopulmonary anas-
tomosis at a somewhat older age (P¼ .03). Two of 45 high-
risk patients (4.4%) and 3 of 117 standard-risk patientsery c October 2010
TABLE 6. Stage 1 palliation postoperative hemodynamics (first 48
hours) by risk level
Variable
High
(n ¼ 45)
Standard
(n ¼ 117)
P
value
Venous SO2 (%) 62  9 62  8 .7
Arterial SO2 (%) 83  4 83  4 .8
Hemoglobin (mg/dL) 15.6  1.5 15.8  1.5 .4
Arteriovenous oxygen content
difference (mL/dL)
4.5  1.8 4.5  1.6 .8
Somatic regional SO2 74  8 78  7 <.009
Cerebral regional SO2 66  9 67  8 .9
Mean arterial pressure (mm Hg) 49  6 51  6 .01
Central venous pressure (mm Hg) 10  3 10  2 .3
Heart rate (beats/min) 175  15 174  15 .3
Pulmonary/systemic blood flow ratio 1.8  1.1 1.7  0.9 .6
Inspired oxygen fraction 0.47  0.13 0.45  11 .3
pH 7.36  0.08 7.40  0.08 <.001
PCO2 (mm Hg) 48  9 44  8 <.001
PO2 (mm Hg) 47  5 46  5 .3
Base excess (mEq/L) 0.3  4.1 1.3  3.9 .02
Systemic VRI 11.1  4.7 11.7  4.4 .3
Total pulmonary VRI 6.9  2.2 7.6  2.4 .08
Milrinone (mg/[kg $ min]) 0.5  0.2 0.5  0.1 .7
Epinephrine (mg/[kg $ min]) 0.09 0.08 0.08  0.09 .13
Norepinephrine (mg/[kg $ min]) 0.04  0.06 0.05  0.09 .5
All data are mean  SD. SO2, Oxygen saturation; VRI, vascular resistance index.
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pulmonary shunt (Table 3). Ages at transplant were similar
at 121  118 days in the high-risk group and 52  15 days
in the standard-risk group (P ¼ .4).
After cavopulmonary anastomosis or cardiac transplant
and before 1 year of age, there were 4 deaths in the high-
risk group and 2 deaths in the standard-risk group. The
high-risk group deaths were 2 patients with Turner syn-
drome, 1 of whom died 2 weeks after takedown of the cav-
opulmonary shunt and 1 with sepsis who died 5 months after
bilateral bidirectional cavopulmonary shunt; a patient with
heterotaxy who had an interstage cardiac arrest requiring
ECMO and died 7 weeks after cavopulmonary anastomosis
with common atrioventricular valvuloplasty; and that of
a low—birth weight premature infant with enterovirus myo-
carditis who died 3.5 months after cavopulmonary shunt.
The 2 standard-risk deaths were a patient with interstage car-
diac arrest requiring ECMO who died after cavopulmonary
anastomosis and atrioventricular valvuloplasty on postoper-
ative day 15 and a patient who died 3 months after cardiac
transplant. Overall, 1-year survival (78% vs 93%,
P ¼ .01) and survival to date (71% vs 92%, P ¼ .001)
were lower among high-risk patients than among standard-
risk patients (Figure 1).DISCUSSION
Previous studies have identified patient-specific risk
factors for early mortality after palliation for HLHS and itsThe Journal of Thoracic and Cavariants, including prematurity, low birth weight, extracar-
diac disease, and additional cardiac anomalies. Early sur-
vival for these high-risk patients has been reported to be
52% to 65%, versus approximately 85% for standard-risk
patients. The absolute incremental mortality risk attributable
to these identified high-risk patient factors ranges from 15%
to 30%.1,3 The point of this study was to assess the effect of
our intensive monitoring and goal-directed strategies on the
absolute mortality risk attributable to these same patient-
specific factors. In the setting of comprehensive monitoring
and goal-directed interventions, we observed a lower opera-
tive mortality burden associated with high-risk patient-spe-
cific factors than previously reported.
During the last decade, we have reported improved early
and intermediate survival for patients undergoing Norwood
palliation with a monitoring strategy including in-hospital
SvO2 measurement and interstage home monitoring of SaO2
and growth velocity.8,9,11,12 Furthermore, in a subset of
patients from 1996 to 2006 with HLHS, as defined by the
International Working Group for Mapping and Coding of
Nomenclatures for Paediatric and Congenital Heart Disease,
our group reported that no patients with low birth weight,
prematurity, or additional extracardiac diagnosis died early
after Norwood palliation with the modified Blalock–Taussig
shunt, suggesting that perioperative goal-directed therapy
may ameliorate the effect of these identified risk factors for
mortality.12 That report excluded patients who had S1P with
right ventricle–pulmonary artery shunt and diagnostic vari-
ants ofHLHS such as unbalanced atrioventricular canal, a pre-
viously reported risk factor for Norwood palliation.18
A limitation of this study is the imbalance between groups
beyond the predetermined risk factors. In addition to smaller
size and younger gestational age, high-risk patients more
commonly included variants of HLHS (38% vs 15%); how-
ever, there was no difference in ascending aorta diameter rel-
ative to the standard-risk group. The high-risk group had
prolonged intraoperative support times; however, vasoactive
support and indices of global oxygen delivery (SvO2, arterio-
venous oxygen content difference) and cerebral SrO2 were
similar between groups. We have previously reported that
the impact of perioperative factors on outcome can be suc-
cessfully minimized with comprehensive monitoring and
goal-directed interventions.9,12 Although more patients in
the high-risk group had S1P with the right ventricle–pulmo-
nary artery conduit, the effect of this difference is not
clear.19-22 In contrast to findings from the National Heart,
Lung, and Blood Institute–sponsored Pediatric Heart
Network Single Ventricle Reconstruction Trial,23 we did
not find a raw survival advantage between shunt types in ei-
ther risk category. Comparison of the propensity-weighted
outcomes between groups to adjust for the imbalance in
shunt types between risk groups may indicate an advantage
to the right ventricle–pulmonary artery conduit in higher-
risk patients.rdiovascular Surgery c Volume 140, Number 4 861
FIGURE 1. Actuarial survivals after Norwood palliation for standard-risk and high-risk patients from September 2000 to September 2008. Operative sur-
vival and survival to cavopulmonary anastomosis are comparable between groups; 1-year survival and survival to date are lower among high-risk patients than
among standard-risk patients (P ¼ .01 and P ¼ .001, respectively).
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the early postoperative period. They were more likely to re-
quire gastrostomy tube placement for nutritional support and
to remain as inpatients until cavopulmonary anastomosis.
High-risk patients who underwent cavopulmonary anasto-
mosis were older than standard-risk patients (129 vs 114
days) but were at similar weights at the time of cavopulmo-
nary anastomosis.
Progression to transplant after S1P was similar between
risk groups. Because transplant is an acceptable alternative
strategy anytime during progression to and beyond Fontan
palliation, we did not equate transplant with death but rather
separated these outcomes. Patients listed for transplant were
considered to be the most fragile and poorest candidates for
cavopulmonary connection on the basis of anatomic or phys-
iologic vulnerabilities identified during the perioperative pe-
riod. These patients also represented a subset considered to
be at greatest risk for death after initial palliation. Survival
to transplant thus may be considered a successful result of
comprehensive perioperative monitoring and goal-directed
interventions as routine adjuncts to therapies. Nonetheless,
the early outcomes between groups were not different
when both transplant and death were counted as failures.
One patient in each group died within 30 days after cav-
opulmonary anastomosis. Death beyond the early post–
cavopulmonary anastomosis period was a feature of the
high-risk group, with 3 patients dying in this interval. Sur-
vival among the high-risk patients were significantly lower
than those among standard-risk patients both at 1 year862 The Journal of Thoracic and Cardiovascular Surg(78% vs 92%) and to date (72% vs 92%; Figure 1). These
results suggest that as long as high-risk patients are subject
to heightened surveillance, similar early survival to that of
standard-risk patients is possible. Although standard-risk pa-
tients enjoy a period of relative lower risk after cavopulmo-
nary anastomosis, this period of relative safety does not
appear to extend to high-risk patients. To achieve results
comparable with those of standard-risk patients, continued
monitoring or alternative therapy such as heart transplant
should be considered for high-risk patients on a case-by-
case basis. Although long-term survival will likely continue
to be lower for some patient groups, such as those with
Turner syndrome, these data suggest that the outcome of
the high-risk group is not fixed but instead can be improved
with continued higher intensity monitoring.CONCLUSIONS
With an intensive monitoring strategy, comparable early
survival was achieved for these patient risk strata. Early
goal-directed treatment of shock has demonstrated survival
value in a wide variety of patients, and the neonatal cardiac
patient is no exception. The therapeutic benefit of a compre-
hensive goal-directed hemodynamic monitoring and treat-
ment strategy is not lost on high-risk cardiac patients, and
the outcomes achieved with this approach exceed previous
published outcomes.
We thank Robert D. B. Jaquiss, MD, for his contribution in
program development and management of this cohort.ery c October 2010
Ghanayem et al Congenital Heart Disease
C
H
DReferences
1. Gaynor JW, Mahle WT, Cohen MI, Ittenbach RF, DeCampli WM, Steven JM,
et al. Risk factors for mortality after the Norwood procedure. Eur J Cardiothorac
Surg. 2002;22:82-9.
2. Pizarro C, Davis DA, Galantowicz ME, Munro H, Gidding SS, Norwood WI.
Stage I palliation for hypoplastic left heart syndrome in low birth weight neonates:
can we justify it? Eur J Cardiothorac Surg. 2002;21:716-20.
3. Stasik CN, Gelehrter S, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Current
outcomes and risk factors for the Norwood procedure. J Thorac Cardiovasc Surg.
2006;131:412-7.
4. Artrip JH, Campbell DN, Ivy DD, Almodovar MC, Chan KC, Mitchell MB, et al.
Birth weight and complexity are significant factors for the management of hypo-
plastic left heart syndrome. Ann Thorac Surg. 2006;82:1252-9.
5. Jacobs JP, O’Brien SM, Chai PJ, Morell VO, Lindberg HL, Quintessenza JA.
Management of 239 patients with hypoplastic left heart syndrome and related
malformations from 1993 to 2007. Ann Thorac Surg. 2008;85:1691-7.
6. Pizarro C, Murdison KA, Derby CD, Radtke W. Stage II reconstruction after
hybrid palliation for high-risk patients with a single ventricle. Ann Thorac
Surg. 2008;85:1382-8.
7. Sano S, Ishino K, Kawada M, Arai S, Kasahara S, Asai T, et al. Right ventricle-
pulmonary artery shunt in first-stage palliation of hypoplastic left heart syndrome.
J Thorac Cardiovasc Surg. 2003;126:504-10.
8. Ghanayem NS, Hoffman GM, Mussatto KA, Cava JR, Frommelt PC, Rudd NA,
et al. Home surveillance program prevents interstage mortality after the Norwood
procedure. J Thorac Cardiovasc Surg. 2003;126:1367-77.
9. Tweddell JS, Hoffman GM, Mussatto KA, Fedderly RT, Berger S, Jaquiss RD,
et al. Improved survival of patients undergoing palliation of hypoplastic left heart
syndrome: lessons learned from 115 consecutive patients. Circulation. 2002;
106(12 Suppl. 1):I82-9.
10. De Oliveira NC, Ashburn DA, Khalid F, Burkhart HM, Adatia IT, Holtby HM,
et al. Prevention of early sudden circulatory collapse after the Norwood operation.
Circulation. 2004;110(11 Suppl. 1):II133-8.
11. Ghanayem NS, Tweddell JS, Hoffman GM, Mussatto K, Jaquiss RD. Optimal
timing of the second stage of palliation for hypoplastic left heart syndrome facil-
itated through home monitoring, and the results of early cavopulmonary anasto-
mosis. Cardiol Young. 2006;16(Suppl. 1):61-6.
12. Tweddell JS, Ghanayem NS, Mussatto KA, Mitchell ME, Lamers LJ, Musa NL,
et al. Mixed venous oxygen saturation monitoring after stage 1 palliation for
hypoplastic left heart syndrome. Ann Thorac Surg. 2007;84:1301-11.The Journal of Thoracic and Ca13. Li J, Zhang G, McCrindle BW, Holtby H, Humpl T, Cai S, et al. Profiles of
hemodynamics and oxygen transport derived by using continuous measured
oxygen consumption after the Norwood procedure. J Thorac Cardiovasc Surg.
2007;133:441-8.
14. Tweddell JS. The Norwood procedure with an innominate artery-to-pulmonary ar-
tery shunt. In: Operative techniques in thoracic and cardiovascular surgery: a com-
parative atlas. 2005;10:123-40.
15. Tweddell JS, Hoffman GM, Fedderly RT, Berger S, Thomas JP Jr, GhanayemNS,
et al. Phenoxybenzamine improves systemic oxygen delivery after the Norwood
procedure. Ann Thorac Surg. 1999;67:161-8.
16. Jaquiss RD, Ghanayem NS, Hoffman GM, Fedderly RT, Cava JR, Mussatto KA,
et al. Early cavopulmonary anastomosis in very young infants after the Norwood
procedure: impact on oxygenation, resource utilization, and mortality. J Thorac
Cardiovasc Surg. 2004;127:982-9.
17. Tchervenkov CI, Jacobs JP, Weinberg PM, Aiello VD, Beland MJ, Colan SD,
et al. The nomenclature, definition and classification of hypoplastic left heart syn-
drome. Cardiol Young. 2006;16:339-68.
18. Owens GE, Gomez-Fifer C, Gelehrter S, Owens ST. Outcomes for patients
with unbalanced atrioventricular septal defects. Pediatr Cardiol. 2009;30:
431-5.
19. Tabbutt S, Dominguez TE, Ravishankar C, Marino BS, Gruber PJ, Wernovsky G,
et al. Outcomes after the stage I reconstruction comparing the right ventricular to
pulmonary artery conduit with the modified Blalock Taussig shunt. Ann Thorac
Surg. 2005;80:1582-91.
20. Bradley SM, Simsic JM, McQuinn TC, Habib DM, Shirali GS, Atz AM. Hemo-
dynamic status after the Norwood procedure: a comparison of right ventricle-
to-pulmonary artery connection versus modified Blalock-Taussig shunt. Ann
Thorac Surg. 2004;78:933-41.
21. Mahle WT, Cuadrado AR, Tam VK. Early experience with a modified Norwood
procedure using right ventricle to pulmonary artery conduit. Ann Thorac Surg.
2003;76:1084-9.
22. Azakie A, Martinez D, Sapru A, Fineman J, Teitel D, Karl TR. Impact of right
ventricle to pulmonary artery conduit on outcome of the modified Norwood pro-
cedure. Ann Thorac Surg. 2004;77:1727-33.
23. Ohye RG, Tabbutt S, Sleeper LA, Pearson GD, Mahoney L, Newburger JW, et al.
Outcomes of the Norwood operation in infants randomized to a modified Blalock-
Taussig versus right ventricle to pulmonary artery shunt: The Pediatric Heart
Network Single Ventricle Reconstruction Trial [abstract]. Circulation. 2009;
120:S560.rdiovascular Surgery c Volume 140, Number 4 863
